Sex differences in associations between creatinine and cystatin C-based kidney function measures with stroke and major bleeding

Lees, J. S. , De La Mata, N. L., Sullivan, M. K. , Wyld, M. L., Rosales, B. M., Cutting, R., Hedley, J. A., Rutherford, E., Mark, P. B. and Webster, A. C. (2023) Sex differences in associations between creatinine and cystatin C-based kidney function measures with stroke and major bleeding. European Stroke Journal, 8(3), pp. 756-768. (doi: 10.1177/23969873231173282)

Abstract

Purpose: We sought to explore whether adding kidney function biomarkers based on creatinine (eGFRCr), cystatin C (eGFRCys) or a combination of the two (eGFRCr-Cys) could improve risk stratification for stroke and major bleeding, and whether there were sex differences in any additive value of kidney function biomarkers. Method: We included participants from the UK Biobank who had not had a previous ischaemic or haemorrhagic stroke or major bleeding episode, and who had kidney function measures available at baseline. Cause-specific Cox proportional hazards models tested associations between eGFRCr, eGFRCys and eGFRCr-Cys (mL/min/1.73 m2) with ischaemic and haemorrhagic stroke, major bleeding (gastrointestinal or intracranial, including haemorrhagic stroke) and all-cause mortality. Findings: Among 452,879 eligible participants, 246,244 (54.4%) were women. Over 11.5 (IQR 10.8–12.2) years, there were 3706 ischaemic strokes, 795 haemorrhagic strokes, 26,025 major bleeding events and 28,851 deaths. eGFRCys was more strongly associated with ischaemic stroke than eGFRCr: an effect that was more pronounced in women (men – HR: 1.16, 95% CI: 1.12–1.19; female to male comparison – HR: 1.11, 95% CI: 1.05–1.16, per 10 mL/min/1.73 m2 decline in eGFRCys). This interaction effect was also demonstrated for eGFRCr-Cys, but not eGFRCr. eGFRCys and eGFRCr-Cys were more strongly associated with major bleeding and all-cause mortality than eGFRCr in both men and women. Event numbers were small for haemorrhagic stroke. Discussion: To a greater degree than is seen in men, eGFRCr underestimates risk of ischaemic stroke and major bleeding in women compared to eGFRCys. The difference between measures is likely explained by non-GFR biology of creatinine and cystatin C. Conclusion: Enhanced measurement of cystatin C may improve risk stratification for ischaemic stroke and major bleeding and clinical treatment decisions in a general population setting, particularly for women.

• Item Type: Articles
• Additional Information: Data access for this work was funded by a Chief Scientist Office Postdoctoral Lectureship awarded to ER (PCL/18/3) and a University of Sydney/University of Glasgow Partnership Award (9241562498).
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Rutherford, Dr Elaine and Mark, Professor Patrick and Sullivan, Dr Michael and Lees, Jennifer
• Authors: Lees, J. S., De La Mata, N. L., Sullivan, M. K., Wyld, M. L., Rosales, B. M., Cutting, R., Hedley, J. A., Rutherford, E., Mark, P. B., and Webster, A. C.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: European Stroke Journal
• Publisher: SAGE
• ISSN: 2396-9873
• ISSN (Online): 2396-9881
• Published Online: 12 May 2023
• Copyright Holders: Copyright © European Stroke Organisation 2023
• First Published: First published in European Stroke Journal 8(3):756-768
• Publisher Policy: Reproduced under a Creative Commons license